Cargando…
A 5-year clinical follow-up study from the Italian National Registry for FSHD
BACKGROUND: The natural history of facioscapulohumeral muscular dystrophy (FSHD) is undefined. METHODS: An observational cohort study was conducted in 246 FSHD1 patients. We split the analysis between index cases and carrier relatives and we classified all patients using the Comprehensive Clinical E...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815626/ https://www.ncbi.nlm.nih.gov/pubmed/32813049 http://dx.doi.org/10.1007/s00415-020-10144-7 |
_version_ | 1783638269716594688 |
---|---|
author | Vercelli, Liliana Mele, Fabiano Ruggiero, Lucia Sera, Francesco Tripodi, Silvia Ricci, Giulia Vallarola, Antonio Villa, Luisa Govi, Monica Maranda, Louise Di Muzio, Antonio Scarlato, Marina Bucci, Elisabetta Maggi, Lorenzo Rodolico, Carmelo Moggio, Maurizio Filosto, Massimiliano Antonini, Giovanni Previtali, Stefano Angelini, Corrado Berardinelli, Angela Pegoraro, Elena Siciliano, Gabriele Tomelleri, Giuliano Santoro, Lucio Mongini, Tiziana Tupler, Rossella |
author_facet | Vercelli, Liliana Mele, Fabiano Ruggiero, Lucia Sera, Francesco Tripodi, Silvia Ricci, Giulia Vallarola, Antonio Villa, Luisa Govi, Monica Maranda, Louise Di Muzio, Antonio Scarlato, Marina Bucci, Elisabetta Maggi, Lorenzo Rodolico, Carmelo Moggio, Maurizio Filosto, Massimiliano Antonini, Giovanni Previtali, Stefano Angelini, Corrado Berardinelli, Angela Pegoraro, Elena Siciliano, Gabriele Tomelleri, Giuliano Santoro, Lucio Mongini, Tiziana Tupler, Rossella |
author_sort | Vercelli, Liliana |
collection | PubMed |
description | BACKGROUND: The natural history of facioscapulohumeral muscular dystrophy (FSHD) is undefined. METHODS: An observational cohort study was conducted in 246 FSHD1 patients. We split the analysis between index cases and carrier relatives and we classified all patients using the Comprehensive Clinical Evaluation Form (CCEF). The disease progression was measured as a variation of the FSHD score performed at baseline and at the end of 5-year follow-up (ΔFSHD score). FINDINGS: Disease worsened in 79.4% (112/141) of index cases versus 38.1% (40/105) of carrier relatives and advanced more rapidly in index cases (ΔFSHD score 2.3 versus 1.2). The 79.1% (38/48) of asymptomatic carriers remained asymptomatic. The highest ΔFSHD score (1.7) was found in subject with facial and scapular weakness at baseline (category A), whereas in subjects with incomplete phenotype (facial or scapular weakness, category B) had lower ΔFSHD score (0.6) p < 0.0001. CONCLUSIONS: The progression of disease is different between index cases and carrier relatives and the assessment of the CCEF categories has strong prognostic effect in FSHD1 patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00415-020-10144-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7815626 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-78156262021-01-25 A 5-year clinical follow-up study from the Italian National Registry for FSHD Vercelli, Liliana Mele, Fabiano Ruggiero, Lucia Sera, Francesco Tripodi, Silvia Ricci, Giulia Vallarola, Antonio Villa, Luisa Govi, Monica Maranda, Louise Di Muzio, Antonio Scarlato, Marina Bucci, Elisabetta Maggi, Lorenzo Rodolico, Carmelo Moggio, Maurizio Filosto, Massimiliano Antonini, Giovanni Previtali, Stefano Angelini, Corrado Berardinelli, Angela Pegoraro, Elena Siciliano, Gabriele Tomelleri, Giuliano Santoro, Lucio Mongini, Tiziana Tupler, Rossella J Neurol Original Communication BACKGROUND: The natural history of facioscapulohumeral muscular dystrophy (FSHD) is undefined. METHODS: An observational cohort study was conducted in 246 FSHD1 patients. We split the analysis between index cases and carrier relatives and we classified all patients using the Comprehensive Clinical Evaluation Form (CCEF). The disease progression was measured as a variation of the FSHD score performed at baseline and at the end of 5-year follow-up (ΔFSHD score). FINDINGS: Disease worsened in 79.4% (112/141) of index cases versus 38.1% (40/105) of carrier relatives and advanced more rapidly in index cases (ΔFSHD score 2.3 versus 1.2). The 79.1% (38/48) of asymptomatic carriers remained asymptomatic. The highest ΔFSHD score (1.7) was found in subject with facial and scapular weakness at baseline (category A), whereas in subjects with incomplete phenotype (facial or scapular weakness, category B) had lower ΔFSHD score (0.6) p < 0.0001. CONCLUSIONS: The progression of disease is different between index cases and carrier relatives and the assessment of the CCEF categories has strong prognostic effect in FSHD1 patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00415-020-10144-7) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-08-19 2021 /pmc/articles/PMC7815626/ /pubmed/32813049 http://dx.doi.org/10.1007/s00415-020-10144-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Communication Vercelli, Liliana Mele, Fabiano Ruggiero, Lucia Sera, Francesco Tripodi, Silvia Ricci, Giulia Vallarola, Antonio Villa, Luisa Govi, Monica Maranda, Louise Di Muzio, Antonio Scarlato, Marina Bucci, Elisabetta Maggi, Lorenzo Rodolico, Carmelo Moggio, Maurizio Filosto, Massimiliano Antonini, Giovanni Previtali, Stefano Angelini, Corrado Berardinelli, Angela Pegoraro, Elena Siciliano, Gabriele Tomelleri, Giuliano Santoro, Lucio Mongini, Tiziana Tupler, Rossella A 5-year clinical follow-up study from the Italian National Registry for FSHD |
title | A 5-year clinical follow-up study from the Italian National Registry for FSHD |
title_full | A 5-year clinical follow-up study from the Italian National Registry for FSHD |
title_fullStr | A 5-year clinical follow-up study from the Italian National Registry for FSHD |
title_full_unstemmed | A 5-year clinical follow-up study from the Italian National Registry for FSHD |
title_short | A 5-year clinical follow-up study from the Italian National Registry for FSHD |
title_sort | 5-year clinical follow-up study from the italian national registry for fshd |
topic | Original Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815626/ https://www.ncbi.nlm.nih.gov/pubmed/32813049 http://dx.doi.org/10.1007/s00415-020-10144-7 |
work_keys_str_mv | AT vercellililiana a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT melefabiano a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT ruggierolucia a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT serafrancesco a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT tripodisilvia a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT riccigiulia a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT vallarolaantonio a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT villaluisa a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT govimonica a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT marandalouise a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT dimuzioantonio a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT scarlatomarina a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT buccielisabetta a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT maggilorenzo a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT rodolicocarmelo a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT moggiomaurizio a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT filostomassimiliano a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT antoninigiovanni a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT previtalistefano a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT angelinicorrado a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT berardinelliangela a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT pegoraroelena a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT sicilianogabriele a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT tomellerigiuliano a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT santorolucio a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT monginitiziana a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT tuplerrossella a5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT vercellililiana 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT melefabiano 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT ruggierolucia 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT serafrancesco 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT tripodisilvia 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT riccigiulia 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT vallarolaantonio 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT villaluisa 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT govimonica 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT marandalouise 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT dimuzioantonio 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT scarlatomarina 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT buccielisabetta 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT maggilorenzo 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT rodolicocarmelo 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT moggiomaurizio 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT filostomassimiliano 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT antoninigiovanni 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT previtalistefano 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT angelinicorrado 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT berardinelliangela 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT pegoraroelena 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT sicilianogabriele 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT tomellerigiuliano 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT santorolucio 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT monginitiziana 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd AT tuplerrossella 5yearclinicalfollowupstudyfromtheitaliannationalregistryforfshd |